No registrations found.
ID
Source
Brief title
Health condition
aging, muscle protein synthesis, gender, inactivity, obesity
Sponsors and support
Intervention
Outcome measures
Primary outcome
Basal and postprandial muscle protein synthesis rates.
Secondary outcome
Rate of protein digestion and absorption.
Background summary
The main objective of the present project is to assess the impact of gender, physical inactivity, and obesity on basal and postprandial muscle protein synthesis rates. This will be investigated in three different substudies:
Substudy A: The impact of gender on basal and postprandial muscle protein synthesis.
Substudy B: The impact of physical inactivity on basal and postprandial muscle protein synthesis.
Substudy C: The impact of obesity on basal and postprandial muscle protein synthesis.
Basal and postprandial muscle protein synthesis will be studies by means of stable isotope methodology and intrinsically labeled milk proteins.
Study objective
1. The postprandial muscle protein synthesis rate is smaller in females as compared with males.
2. Short-term physical inactivity reduces basal and postprandial muscle protein synthesis rates.
3. Basal and postprandial muscle protein rates are blunted in obese as compared to lean individuals.
Study design
Subjects participate in a screening session and a single test day. During the test day, frequent blood samples and muscle biopsies will be taken for the assessment of basal and postprandial muscle protein synthesis. Basal muscle protein synthesis will be assessed over a 2-hour period, and postprandial muscle protein synthesis will be assessed over a 5-hour period.
Intervention
Substudy A: During a single test day, subjects will undergo continuous intravenous tracer infusions of labelled amino acids, and subjects ingest a beverage containing 25 gram intrinsically labelled milk protein. Blood plasma samples and muscle biopsies will be collected during the test day.
Substudy B: Five days of unilateral knee immobilization will be followed by a single test day. During the test day, subjects undergo continuous intravenous tracer infusions of labelled amino acids, and subjects ingest a drink containing 25 gram intrinsically labelled milk protein. Blood plasma samples and muscle biopsies will be collected during the test day.
Substudy C: During a single test day, subjects undergo continuous intravenous tracer infusions of labelled amino acids, and subjects ingest a drink containing 25 gram intrinsically labelled milk protein. Blood plasma samples and muscle biopsies will be collected during the test day.
Inclusion criteria
Subgroup A:
-Males and females
-Aged between 30-55 years
-BMI 19-25 kg/m2
Subgroup B:
-Male
-Aged between 18-35 years
-BMI 19-30 kg/m2
Subgroup C:
-Male
-Aged between 30-55 years
-BMI >35 kg/m2
Exclusion criteria
Subgroup A:
-Currently smoking cigarettes or tobacco
-Allergies to milk proteins (whey or casein)
-A history of neuromuscular problems
-Diagnosed impaired renal (kidney stones, nephritis, nephritic syndrome, end-stage renal disease) or liver function (acute or chronic hepatitis, alcoholic liver disease, liver cirrhosis)
-Use of medications known to affect digestion and/or absorption (antacids, H-2-receptor blockers, proton pump inhibitors, NSAID’s) 7 days prior to the experimental test-day.
-Use of anticoagulants, blood diseases, allergy for lidocain
-Use of medications known to affect protein metabolism (i.e. corticosteroids, non-steroidal anti-inflammatories, or acne medications).
-Type 2 diabetes (exclusion when: fasting glucose level >7.0 mmol/L, or 2-h glucose level>11.1 mmol/l, or HbA1c >6.5%.
Subgroup B:
-Currently smoking cigarettes or tobacco
-Allergies to milk proteins (whey or casein)
-Arthritic conditions
-History of neuromuscular problems
-History of deep venous thrombosis (DVT) or pulmonary emboli (PE).
-Diagnosed impaired renal (kidney stones, nephritis, nephritic syndrome, end-stage renal disease) or liver function (acute or chronic hepatitis, alcoholic liver disease, liver cirrhosis)
-Use of medications known to affect digestion and/or absorption (antacids, H-2-receptor blockers, proton pump inhibitors, NSAID’s) 7 days prior to the experimental test-day
-Use of anticoagulants, blood diseases, allergy for lidocain
-Use of medications known to affect protein metabolism (i.e. corticosteroids, non-steroidal anti-inflammatories, or acne medications).
-Type 2 diabetes (HbA1c >6.5%).
Subgroup C:
-Allergies to milk proteins (whey or casein)
-A history of neuromuscular problems
-Diagnosed impaired renal (kidney stones, nephritis, nephritic syndrome, end-stage renal disease) or liver function (acute or chronic hepatitis, alcoholic liver disease, liver cirrhosis)
-Use of anticoagulants, blood diseases, allergy for lidocain
-Use of medications known to affect protein metabolism (i.e. corticosteroids, non-steroidal anti-inflammatories, or acne medications).
-Diagnosed type 2 diabetes, and/or use of blood glucose lowering medication.
Design
Recruitment
Followed up by the following (possibly more current) registration
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
| Register | ID |
|---|---|
| NTR-new | NL3898 |
| NTR-old | NTR4060 |
| CCMO | NL42551.068.12 |
| ISRCTN | ISRCTN wordt niet meer aangevraagd. |
| OMON | NL-OMON41407 |